스크랩/신문 기사

Cancer vaccine using mRNA technology boosts survival, says Moderna

JNKIM 2022. 12. 13. 21:16

https://www.ft.com/content/455ef4e3-b870-4baa-9b05-977329e24356

 

Cancer vaccine using mRNA technology boosts survival, says Moderna

Data show combination with Merck’s immunotherapy drug reduced possibility of death in high-risk patients

www.ft.com

https://www.biospace.com/article/releases/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-r-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-942-trial/

 

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R)

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial o

www.biospace.com

 "Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone."

저작자표시 비영리